Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia By Ogkologos - March 26, 2026 205 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RECITE study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... May 10, 2022 Disparities in Cancer Care Between Citizens and Refugees in Lebanon March 23, 2021 Men’s skin cancer rates increase by 50% over decade June 24, 2021 Stimulating the Immune System Shrinks Some Slow-Growing Lymphomas September 26, 2018 Load more HOT NEWS Helping Kids with Cancer Speak for the Supportive Care They Need Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs Help seeking: Why isn’t it as simple as it might sound? Five Questions With…Fern, Christina, Mary, and Shelley.
